Skip to content

Screening Education And Recognition by primary Care pHysician of Atrial Fibrillation for prevention of stroke (SEARCH-AF II)

In an ambulatory population over 65 years of age attending general practices, is a handheld single-lead ECG attached to an iPhone an acceptable and effective screening tool to identify atrial fibrillation?

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000429752
Acronym
SEARCH-AF II
Enrollment
88
Registered
2013-04-16
Start date
2013-05-01
Completion date
2013-10-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Atrial fibrillation (AF) is the most common heart arrhythmia affecting at least 240,000 Australians. Prevalence rises with age from approximately 1% of the whole population to 5% in those over 65 years. People with AF are up to seven times more likely to have a stroke than the general population, and AF related strokes are also likely to be more severe. In addition, one in every six strokes is AF related. Stroke is highly preventable in AF with the use of appropriate thromboprophylaxis. Therefore early identification and appropriate evidence based management of AF could lead to subsequent stroke prevention, significant reduction in the overall stroke burden and substantial savings to the health system. The study is designed to examine the feasibility of screening to identify undiagnosed AF in a primary care setting. Our hypothesis is that a simple primary care screening program may be effective in detecting those with undiagnosed AF. The specific aims are to: 1. Assess the feasibility and acceptability of screening for AF using a hand-held single-lead ECG device in people aged 65 years and over in the general practice setting. 2. Assess the satisfaction of GPs, reception staff and patients with the screening process in the general practice setting. 3. Examine process measures, such as the time taken to complete the intervention, competing demands for practice reception staff time, and the attitudes of patients and staff involved in the intervention. 4. Identify barriers (including technological barriers), enablers and other information relevant to the process of developing a larger-scale implementation study. We propose a cross-sectional study offered in up to 5 general practices in the Sydney metropolitan area. People aged 65 and over, attending general practices will be invited to volunteer for the screening. The screening will consist of an assessment with a handheld single-lead ECG device attached to an iPhone by the practice receptionist. This ECG will be transmitted to a secure website and reviewed by the patient's GP during their consultation. The primary outcome measure will be the acceptability of the screening process. A process evaluation will also be undertaken to better appreciate factors that might influence sustainability beyond the trial setting.

Interventions

Receptionists in general practice clinics will be trained to screen eligible patients for atrial fibrillation using a handheld single-lead ECG (the AliveCor Heart Monitor for iPhone). This will be a one-off screening of approximately 30 seconds duration. Following the screening, the iPhone will transmit a pdf of the ECG recording to a secure website toghether with an automated computer diagnosis of whether the patient is likely to have atrial fibrillation or not. During the patient's consultatio

Receptionists in general practice clinics will be trained to screen eligible patients for atrial fibrillation using a handheld single-lead ECG (the AliveCor Heart Monitor for iPhone). This will be a one-off screening of approximately 30 seconds duration. Following the screening, the iPhone will transmit a pdf of the ECG recording to a secure website toghether with an automated computer diagnosis of whether the patient is likely to have atrial fibrillation or not. During the patient's consultation, the GP will log in to the secure website and review the ECG. The GP will advise the patient if any additional treatment is required. The screening trial will be conducted over a 6 month period.

Sponsors

The George Institute for Global Health
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

People will be eligible to participate if they are attending the general practice for a consultation with their GP and are aged 65 years or over.

Exclusion criteria

Exclusion criteria include: a. diagnosis of a severe coexisting medical condition that would prevent participation (eg, dementia, terminal illness); or b. the inability to read/understand the consent form and participant information statement in English.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026